Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Jan 21;2009(1):CD006406.
doi: 10.1002/14651858.CD006406.pub2.

Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors

Samreen Siddiq  1 , Derwood Pamphilon, Susan Brunskill, Carolyn Doree, Chris Hyde, Simon Stanworth
Affiliations
Comparative Study

Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors

Samreen Siddiq et al. Cochrane Database Syst Rev. .

Abstract

Background: Haemopoietic stem cells can be collected from a donor either as a bone marrow harvest or by peripheral blood collection. Both techniques have risks for the donor.

Objectives: The aim of this review was to identify the adverse effects of haemopoietic stem cell donation and to compare the tolerability and safety of the two methods.

Search strategy: We searched bibliographic databases including the Cochrane Central Register of Controlled trials (CENTRAL) (The Cochrane Library 2008, issue 2), MEDLINE and EMBASE up to May 2008. We also searched reference lists of articles and contacted experts in the field.

Selection criteria: Randomised controlled trials enrolling haemopoietic stem cell donors and evaluating the different methods of donating haemopoietic stem cells were eligible.

Data collection and analysis: Two authors independently screened studies for inclusion. We extracted data and evaluated methodological quality. Quantitative analysis was not possible for most outcomes, but where used we preferred random-effects models due to the variability between the included studies.

Main results: Six trials (807 donors) were eligible: all were substudies, or constituent parts of, larger randomised controlled trials of bone marrow and peripheral blood stem cell allogeneic transplantation. No included trial was designed solely to measure and assess the experience of stem cell donors. The donors in all studies were related to the stem cell recipient. Overall, both types of donors experienced pain subsequent to donation, and psychological morbidity. The trend was for bone marrow donors to experience more pain at the donation site, more overall adverse events, and more days of restricted activity. They were also more likely to require hospitalisation than peripheral blood stem cell donors. In contrast, peripheral blood stem cell donors experienced more pain prior to donation, which may be related to the pre-donation administration of granulocyte colony stimulating factor (G-CSF). The methodological quality of the studies was poor and indicated limitations due to the risk of selection and attrition bias. The proportion of donors from the parent trial not included in the donor substudies was also inadequately explained.

Authors' conclusions: The different short-term morbidities associated with each type of haemopoietic stem cell donation were clear, with bone marrow donors experiencing more pain and more restriction post-donation than peripheral blood donors. However, the studies were limited by their methodological quality, failure to provide long-term follow up (for which larger numbers of donors would be required) and a failure to apply consistent measures of quality of life in a way which allows more meaningful evaluation across studies.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Quorum statement
2
2
Forest plot of comparison: 1 Donor difficulty in functioning following stem cell harvest, outcome: 1.1 Number of donors returning to normal activity by day 7 following procedure.
3
3
Forest plot of comparison: 2 Donor mortality, outcome: 2.1 Donor mortality 23‐28 months following stem cell donation.
1.1
1.1. Analysis
Comparison 1 Pain, Outcome 1 Mean pain score (mm): Fortainer 2002.
2.1
2.1. Analysis
Comparison 2 Donor difficulty in functioning following stem cell harvest, Outcome 1 Number of donors returning to normal activity by day 7 following procedure.
3.1
3.1. Analysis
Comparison 3 Donor mortality, Outcome 1 Donor mortality 23 to 28 months following stem cell donation.
See this image and copyright information in PMC

Comment in

References

References to studies included in this review

Bredeson 2004 {published data only}
    1. Bredeson C, Leger C, Couhan S, Simpson D, Huebsch L, Walker I, et al. An evaluation of the donor experience in the Canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biology of Bone and Marrow Transplantation 2004;10:405‐14. - PubMed
Favre 2003 {published data only}
    1. Favre G, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplantation 2003;32(9):873‐80. - PubMed
Fortanier 2002 {published data only}
    1. Fortanier C, Kuentz M, Sutton L, Milpied N, Michalet M, Macquart‐Moulin G, et al. Healthy sibling donor anxiety and pain during bone marrow or peripheral blood stem cell harvesting for allogeneic transplantation: results of a randomised study. Bone Marrow Transplantation 2002;29:145‐9. - PubMed
Heldal 2002 {published data only}
    1. Heldal D, Brinch L, Tjonnfjord G, Solheim BG, Egeland T, Gadeholt G, et al. Donation of stem cells from blood or bone marrow: results of a randomised study of safety and complaints. Bone Marrow Transplantation 2002;29:479‐86. - PubMed
Kennedy 2003 {published data only}
    1. Kennedy GA, Morton J, Western R, Butler J, Daly J, Durrant S. Impact of stem cell donation modality on normal donor quality of life: a prospective randomised study. Bone Marrow Transplantation 2003;31:1033‐5. - PubMed
Rowley 2001 {published data only}
    1. Rowley SD, Donaldson G, Lilleby K, Bensinger WI, Applebaum FR. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 2001;97(9):2541‐8. - PubMed

References to studies excluded from this review

Beyer 1993 {published data only}
    1. Beyer J, Schwella N, Stroscheer I, Schwaner I. Randomised comparison of haemopoietic rescue with stem/progenitor cells from bone marrow or peripheral blood after high‐dose chemotherapy in germ cell tumors. Bone Marrow Transplantation 1994;14(Supplement 1):S45.
Beyer 1994 {published data only}
    1. Beyer J, Schwella N, Zingsem J, Strohscheer I, Schwaner I, et al. Bone marrow versus peripheral blood stem cells as rescue after high‐dose chemotherapy. Blood 1993;82:454a. - PubMed
Clark 2000 {published data only (unpublished sought but not used)}
    1. Clark R. Protocol for the collection and transplantation of peripheral blood stem cells from unrelated donors. National Research Register ‐ N0207073104.
Ho 1996 {published data only}
    1. Ho AD, Young D, Maruyama M, Law P, Corringham ET, Mason JR. Mobilization and purification of CD34+ cells from normal donors ‐ regimens with G‐CSF, GM‐CSF, or a combination of both. Bone Marrow Transplantation 1996;17(Suppl 2):S34‐S37. - PubMed
Hutchinson 1997 {unpublished data only}
    1. Hutchinson R. Phase II randomised, multicentre trial comparing the safety and feasability of allogeneic filgrastim‐mobilised peripheral blood progenitor cell transplantation (PBPCT) with allogeneic bone marrow transplantation (BMT). National Research Register Document ‐ N0123090369 1997.
Karlsson 2004 {published data only}
    1. Karlsson L, Quinlan D, Guo D, Brown C, Selinger S, Klassen J, et al. Mobilised blood cells vs bone marrow harvest: experience compared in 171 donors with particular reference to pain and fatigue. Bone Marrow Transplantation 2004;33(7):709‐13. - PubMed
Kulkarni 1998 {unpublished data only}
    1. Kulkarni S, Singhal S, Powles R, Neville F, Shaw K, Antrum J, et al. Donor preference assessment regarding bone marrow (BM) versus lenograstim mobilized peripheral stem cells (PBSC) for allograft. Blood 1998;92(10 Suppl 1 (Pt1)):141a.
Lorigan 2006 {published data only}
    1. Lorigan P. The use of unrelated donors for the collection of peripheral blood stem cell for transplantation. National Research Register ‐ N0276081490 2000.
Rogers 1996 {unpublished data only}
    1. Rogers J. Allogeneic PBSCT ‐ the implications for donors. Bone Marrow Transplant 1996;17:S156.
Singhal 1996 {published data only}
    1. Singhal S, Powles R, Treleaven J, Long S, Rowland A, Mehta J. Harvesting both marrow and G‐CSF mobilised blood stem cells within a week in healthy donors: clinical and haematologic consequences. British Journal of Haematology 1996;93(Suppl 2):258.
Switzer 2001 {published data only}
    1. Switzer GE, Goycoolea JM, Dew MA, Graeff EC, Hegland J. Donating stimulated peripheral blood stem cells vs bone marrow: Do donors experience the procedures differently?. Bone Marrow Transplantation 2001;27(9):917‐23. - PubMed

Additional references

Arshad 2005
    1. Arshad M, Seiter K, Bilaniuk J, Qureshi A, Patil A, Ramaswamy G, et al. Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim. Journal of Clinical Oncology 2005;23(33):8533‐4. - PubMed
Balaguer 2004
    1. Balaguer H, Galmes A, Ventayol G, Bargay J, Besalduch J. Splenic rupture after granulocyte colony‐stimulating factor mobilisation in a peripheral blood progenitor cell donor. Transfusion 2004;44(8):1260‐1. - PubMed
Bennett 2006
    1. Bennett CL, Evens AM, Andristos LA, Balasubramanian L, Mai M, Fisher MJ, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. British Journal of Haematology 2006;135(5):651‐2. - PubMed
Brown 1997
    1. Brown SL, Dale DC. Spontaneous splenic rupture following administration of granulocyte colony‐stimulating factor (G‐CSF): occurence in an allogeneic donor of peripheral blood stem cells. Biology of Blood and Marrow Transplantation 1997;3(6):341‐3. - PubMed
Buckner 1984
    1. Buckner CD, Clift RA, Sanders JE, Stewart P, Bensinger WI, Doney KC. Marrow harvesting from normal donors. Blood 1984;64(3):630‐4. - PubMed
Dincer 2004
    1. Dincer AP, Gottschall J, Margolis DA. Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilisation. Journal of Paediatric Haematology and Oncology 2004;26(11):761‐3. - PubMed
Falzetti 1999
    1. Falzetti F, Aversa F, Minelli O, Tabillio A. Spontaneous rupture of spleen during peripheral blood stem cell mobilization in a healthy donor. Lancet 1999;353(9152):555. - PubMed
Goldman 2006
    1. Goldman JM, Madrigal JA, Pamphilon D. Possible harmful effects of short course granulocyte‐colony‐stimulating factor in normal donors. British Journal of Haematology 2006;135(5):651‐2. - PubMed
Gratwohl 2007
    1. Gratwohl A, Baldomero HK, Frauendorfer K, Urbano‐Ispizua, Niederweiser D. Results of the EBMT activity survey 2005 on haemopoietic stem cell transplantation focus on increasing use of unrelated donors for the Joint Accreditation Committee of the International Society for Cellular Therapy: ISCT and the European Group for Blood and Marrow Transplantation: EBMT (JACIE). Bone Marrow Transplantation 2007;39:71‐87. - PubMed
Hasenclever 1996
    1. Hasenclever D, Sextro M. Safety of AlloPBPCT donors: biometrical considerations on monitoring long‐term risks. Bone Marrow Transplantation 1996;17(Suppl 2):S28‐30. - PubMed
Higgins 2006
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Review of Interventions [updated September 2006]. The Cochrane Library, Issue 4, 2006. Chichester: John Wiley & Sons Ltd, 2006.
Juni 2001
    1. Jüni P, Altman DG, Egger M. Systematic Reviews in Health Care: assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42‐6. - PMC - PubMed
Kasper 1999
    1. Kasper C, Jones L, Fujita Y, Morgenstern GR, Scarffe JH, Chang J. Splenic rupture in a patient with acute myeloid leukemia undergoing peripheral blood stem cell transplantation. Annals of Haematology 1999;78(2):91‐2. - PubMed
Kuendgen 2006
    1. Kuendgen A, Fenk R, Bruns I, Dommach M, Schutte A, Engers R, et al. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 2006;38(1):69‐70. - PubMed
Nishimori 2002
    1. Nishimori M, Yamada Y, Hoshi K, Akiyama Y, Hoshi Y, Morishima Y. Health related quality of life of unrelated bone marrow donors in Japan. Blood 2002;99(6):1995‐2000. - PubMed
Nuamah 2006
    1. Nuamah NM, Goker H, Kilic YA, Dagmoura H, Cakmak A. Spontaneous splenic rupture in a healthy allogeneic donor of peripheral‐blood stem cell following the administration of granulocyte colony‐stimulating factor (G‐CSF). A case report and review of the literature. Haematologica 2006;91(Suppl 5):ECR08. - PubMed
O'Malley 2003
    1. O'Malley DP, Whalen M, Banks PM. Spontaneous splenic rupture with fatal outcome following G‐CSF administration for myelodysplastic syndrome. American Journal of Haematology 2003;73(4):294‐5. - PubMed
Pamphilon 2008
    1. Pamphilon D, Nacheva E, Navarette C, Madrigal A, Goldman J. The use of granulocyte‐colony‐stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion 2008;48(7):1495‐1501. - PubMed
Review Manager 2008 [Computer program]
    1. The Cochrane Collaboration. Review Manager (Rev Man). Version 5.0. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2008.
Switzer 2002
    1. Switzer GE, Goycoolea JM, Dew MA, Graeff EC, Hegland J. Donating stimulated peripheral blood stem cells vs. bone marrow: do donors experience the procedures differently?. Bone Marrow Transplantation 2001;27(9):917‐23. - PubMed
Veerappan 2007
    1. Veerappan R, Morrison M, Williams S, Variakojis D. Splenic rupture in a patient with plasma cell myeloma following G‐CSF/GM‐CSF administration for stem cell transplantation: review of the literature. Bone Marrow Transplant 2007;40(4):361‐4. - PubMed
Watring 2007
    1. Watring NJ, Wagner TW, Stark JJ. Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non‐small cell lung carcinoma. American Journal of Emergency Medicine 2007;25(2):247‐8. - PubMed
www.bmdw.org
    1. Bone marrow donors worldwide. http://www.bmdw.org/.

MeSH terms

Substances

LinkOut - more resources